Theranostics 2018; 8(7):2061-2063. doi:10.7150/thno.24454 This issue


Resistant to Targeted Therapy - Aim for Metabolic Liabilities

André Lima Queiroz, Helin Vakifahmetoglu-Norberg, Erik Norberg

Department of Physiology and Pharmacology, Karolinska Institutet, Nanna Svartz väg 2, SE-171 77, Stockholm, Sweden

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license ( See for full terms and conditions.
Queiroz AL, Vakifahmetoglu-Norberg H, Norberg E. Resistant to Targeted Therapy - Aim for Metabolic Liabilities. Theranostics 2018; 8(7):2061-2063. doi:10.7150/thno.24454. Available from

File import instruction

Commentary-article in Theranostics, Volume 8, 1808


The advent of targeted therapies generated much optimism when discovered. Targeted therapies, are however associated with rapid acquisition of resistance. In a recent study by Dong et al. (Theranostics 2018; 8(7):1808-1823. doi:10.7150/thno.23177) it was shown that lung tumors resistant to the EGFR-inhibitor (Erlotinib), reprogram their metabolism and acquire a pro-survival dependency on Phosphoglycerate Dehydrogenase (PHGDH) that can be targeted to eliminate resistant tumors.

Keywords: EGFR, Lung Cancer, Non-small Cell Lung Carcinomas, Lung Adenocarcinomas, PHGDH, Tumor Metabolism, Serine